Literature DB >> 21507844

Making a case for acute ischemic stroke.

Kathleen A Baldwin1, Stacey L McCoy.   

Abstract

Stroke is the third leading cause of death in the United States and the number one cause of adult long-term disability. Disability in stroke survivors includes hemiparesis, aphasia, inability to walk without assistance, dependence on others for activities of daily living, depression, and institutionalization. Immediate recognition of acute ischemic stroke (AIS) signs and symptoms is required because many treatment options are time sensitive. Hospital transport via activation of 911 and emergency medical services (EMSs) removes delays to urgent diagnosis and intervention. Intravenous (IV) recombinant tissue plasminogen (rt-PA) is a time-sensitive reperfusion strategy. The American Heart Association (AHA) and American Stroke Association (ASA) recently revised recommendations that the time window for IV rt-PA be expanded from 3 hours to 4.5 hours after symptom onset in patients with mild to moderate stroke. Supportive therapies include crystalloid IV solutions, adequate oxygenation, and normothermia. Best rest is desired along with oxygen supplementation. Avoidance of fever is paramount since fever can contribute to negative outcomes. It is the purpose of this article to review risk factors, stroke symptoms, epidemiology, and current drug therapy of AIS. Standards of care will be reviewed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21507844     DOI: 10.1177/0897190010372325

Source DB:  PubMed          Journal:  J Pharm Pract        ISSN: 0897-1900


  2 in total

1.  Decreased plasma miR-335 expression in patients with acute ischemic stroke and its association with calmodulin expression.

Authors:  Bin Zhao; Zilong Zhu; Junwei Hao; Zongming Wan; Xiaoqin Guo
Journal:  J Int Med Res       Date:  2016-11-18       Impact factor: 1.671

2.  Perioperative Ischemic Stroke in Unruptured Intracranial Aneurysm Surgical or Endovascular Therapy.

Authors:  Hind A Beydoun; May Beydoun; Alan Zonderman; Shaker M Eid
Journal:  Cureus       Date:  2020-04-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.